文献速递眼底病与葡萄膜炎

AAV2递送sFLT-1与shVEGF双靶点抗VEGF策略治疗视网膜新生血管

Dual VEGF-Targeting Strategy Via AAV2-Delivered sFLT-1 and shVEGF for Retinal Neovascularization Therapy.
PubMed 文献 · Invest Ophthalmol Vis Sci · 2025-01-01

研究在小鼠氧诱导视网膜病变(OIR)模型中,经玻璃体腔注射AAV2载体分别或联合递送sFLT-1与shVEGF,评估其对视网膜新生血管的疗效。三种基因治疗组均抑制病理性新生血管,AAV2-shVEGF组促进中央无灌注区消退最强,AAV2-sFLT-shVEGF组抑制新生血管生长与炎症浸润更有效,且仅该联合组明显恢复视网膜功能。作者认为AAV2-sFLT-shVEGF双抑制是视网膜新生血管疾病有前景的治疗途径。

要点

  • 三种AAV2基因治疗组均有效抑制OIR小鼠病理性新生血管,疗效存在细微差异。
  • AAV2-shVEGF组促进中央无灌注区消退最强,AAV2-sFLT-shVEGF组抑制新生血管生长与炎症浸润更有效。
  • 仅AAV2-sFLT-shVEGF组显示出明显的视网膜功能恢复能力。

核心结论

  • 作者认为,AAV2-sFLT-shVEGF双抑制为视网膜新生血管疾病提供了有前景的治疗途径,可减少新生血管并改善视网膜健康。

研究设计与样本

  • P12小鼠分为六组:正常组、对照组、AAV2-EGFP组、AAV2-sFLT组、AAV2-shVEGF组和AAV2-sFLT-shVEGF组。
  • 经玻璃体腔注射向氧诱导视网膜病变(OIR)小鼠给予编码sFLT-1、shVEGF或两者组合的AAV2载体。
  • 采用眼底照相与荧光素眼底血管造影(FFA)评估视网膜血管形态与密度,苏木精-伊红(H&E)染色观察视网膜新生血管生长特征。
  • 用免疫荧光与定量PCR(qPCR)评估血管生成因子、炎症介质及血视网膜屏障相关标志物表达,并行视网膜电图(ERG)评估视网膜功能。

主要发现

  • 三种基因治疗组均有效抑制OIR小鼠病理性新生血管,但治疗结果存在细微差异。
  • AAV2-shVEGF组在促进中央无灌注区消退方面疗效最强。
  • AAV2-sFLT-shVEGF组在抑制新生血管生长和炎症浸润方面更有效。
  • 三组在降低血管生成因子表达和增强血视网膜屏障相关标志物方面效果相当。
  • 仅AAV2-sFLT-shVEGF组显示出明显的视网膜功能恢复能力。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Retinal neovascular diseases, often associated with elevated vascular endothelial growth factor (VEGF) levels, are major causes of blindness. Current therapies lack sustained efficacy and safety. This study aimed to evaluate the effectiveness of an adeno-associated virus 2 (AAV2)-based gene therapy vector carrying soluble fms-like tyrosine kinase-1 (sFLT-1) and short hairpin RNA targeting VEGF (shVEGF) in treating retinal neovascularization. METHODS: P12 mice were divided into six groups: normal group, control group, AAV2-EGFP group, AAV2-sFLT group, AAV2-shVEGF group, and AAV2-sFLT-shVEGF group. AAV2 vectors encoding sFLT-1 alone, shVEGF alone, or a combination of both sFLT-1 and shVEGF were administered to oxygen-induced retinopathy (OIR) mice via intravitreal injection. Fundus photography and fluorescein fundus angiography (FFA) were used to evaluate retinal vascular morphology and density. Hematoxylin and eosin (H&E) staining was used to observe the growth characteristics of retinal neovascularization. The expression levels of angiogenic factors, inflammatory mediators, and blood-retina barrier-associated markers were assessed using immunofluorescence and quantitative PCR (qPCR). Electroretinography (ERG) was performed to evaluate retinal function. RESULTS: All three gene therapy groups effectively suppressed pathological neovascularization in OIR mice, although their therapeutic outcomes showed subtle differences. The AAV2-shVEGF group demonstrated the strongest efficacy in promoting the regression of the central non-perfusion area. The AAV2-sFLT-shVEGF group was more effective in suppressing neovascular growth and inflammatory infiltration. All three groups exhibited comparable effects in reducing angiogenic factor expression and enhancing blood-retina barrier-related markers. Notably, only the AAV2-sFLT-shVEGF group showed a pronounced ability to restore retinal function. CONCLUSIONS: Dual inhibition with AAV2-sFLT-shVEGF offers a promising therapeutic approach for retinal neovascular diseases, demonstrating efficacy in reducing neovascularization and improving retinal health.

来源:Invest Ophthalmol Vis Sci,查看原文。版权归原作者所有。

引用

  1. Chen C, Yang X, Jiang Z, et al. Dual VEGF-Targeting Strategy Via AAV2-Delivered sFLT-1 and shVEGF for Retinal Neovascularization Therapy. Invest Ophthalmol Vis Sci. 2025. PMID: 40810574. doi:10.1167/iovs.66.11.37

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。